Frequency and associated risk factors of cardiovascular autonomic neuropathy among patients with type 2 Diabetes
DOI:
https://doi.org/10.31053/1853.0605.v75.n2.17566Keywords:
diabetes mellitus, diabetes complications, diabetic neuropathyAbstract
Background: Cardiovascular autonomic neuropathy (CAN) is a common complication of diabetes and is associated with cardiovascular morbidity and mortality. Despite its prevalence, it is usually underdiagnosed. Objective to assess frequency of CAN in type 2 diabetes, treated at the Diabetology Service at Cordoba Hospital, Argentina.
Methods: Cross-sectional study was conducted from May 2015 to May 2016. Cardiovascular Autonomic Tests (Ewing´s battery) were performed: response to Valsalva maneuver, expiration-to-inspiration ratio (E/I ratio), standing to lying flat and postural hypotension.
Results: 100 type 2 diabetes patients, 53% females. The mean age and diabetes duration 52 years old and 8.4 years, respectively. Hemoglobin A1c level of 8.7% and 47% were insulin-requiring type 2 diabetes patients. 29% had early CAN, 54% confirmed CAN (10% severe CAN) and 17% normal cardiovascular tests. Confirmed CAN was higher in those with longer duration of diabetes; longer duration of insulin therapy, older patients and severe hypoglycemia events was higher in those with confirmed CAN versus without CAN or early CAN (p 0.003). The risk factors associated were hypertension OR 2.55 (p 0.02), peripheral neuropathy OR 11.7 (p <0.0001), diabetic retinopathy OR 9.03 (p 0.001), diabetic nephropathy OR 3.12 (p 0.03) and hemoglobin A1c > 7% OR 2.57 (p 0, 03).
Conclusions: frequency of CAN was high, was associated with hypertension, microvascular complications, older age, poor metabolic control, longer duration of disease and insulin therapy. Patients with a higher risk of developing CAN should be identified, in order to reduce the impact of this complication.
Downloads
References
International Diabetes Federation. IDF Diabetes Atlas. 7th ed. Brussels: IDF;
Aronson D. Pharmacologic modulation of autonomic tone: implications for the
diabetic patient. Diabetologia. 1997 Apr; 40(4):476-81.
Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic Somatic Neuropathies.
Diabetes Care. 2004 Jun; 27(6):1458-86.
Jadzinsky M. Revista de la Sociedad Argentina de Diabetes 1992; 26:93-96.
Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy.
Diabetes Care. 2003; 26(5):1553-79.
Documento de Consenso. Neuropatía diabética. Clasificación, diagnóstico,
control metabólico y tratamiento. Rev Soc Arg de Diabetes 1993; 27(3):3-14.
Jornadas de Actualización sobre Neuropatía Autonómica Diabética. Rev. Soc.
Arg. de Diabetes 2003; 37(3):149-158.
Balcıoğlu AS, Müderrisoğlu H . Diabetes and cardiac autonomic neuropathy:
Clinical manifestations, cardiovascular consequences, diagnosis and treatment.
World J Diabetes. 2015 Feb 15; 6(1):80-91.
Neil HA, Thompson AV, John S, McCarthy ST, Mann JI. Diabetic Autonomic
neuropathy: the prevalence of impaired heart rate variability in a geographically
defined population. Diabet Med. 1989 Jan-Feb; 6(1):20-4.
EURODIAB IDDM Complications Study Group. Microvascular and acute
complications in IDDM patients: the EURODIAB IDDM Complications Study.
Diabetologia. 1994 Mar; 37(3):278-85.
Ziegler D, Gries FA , Mühlen H , Rathmann W , Spüler M , Lessmann F .
Prevalence and Clinical correlates of cardiovascular autonomic and peripheral
diabetic neuropathy in patients attending diabetes centers. The DiaCAN
Multicenter Study Group. Diabete Metab. 1993;19(1 Pt 2):143-51.
Spallone V, Bellavere F , Scionti L , Maule S, Quadri R , Bax G , et al.
Diabetic Neuropathy Study Group of the Italian Society of Diabetology.
Recomendations for the use of cardiovascular test in diagnosing diabetic
autonomic neuropathy. Nutr Metab Cardiovasc Dis. 2011 Jan; 21(1):69-78.
Witte DR, Tesfaye S, Chaturvedi N, Eaton SE, Kempler P , Fuller JH , et al.
EURODIAB prospective complications study group. Risk factors for cardiac
autonomic neuropathy in type 1 diabetes mellitus. Diabetologia. 2005 Jan;
(1):164-71.
Ko SH, Park SA, Cho JH , Song KH , Yoon KH , Cha BY , Son HY, et al.
Progression of cardiovascular autonomic dysfunction in patients with type 2
diabetes: a 7-year follow-up study. Diabetes Care. 2008 Sep; 31(9):1832-6.
Pop-Busui R. Cardiac Autonomic Neuropathy in Diabetes. A clinical
perspective. Diabetes Care, 2010; 33 (2): 434-441.
Maser RE, Pfeifer MA, Dorman JS, Kuller LH, Becker DJ, Orchard TJ. Diabetic
autonomic neuropathy and cardiovascular risk. Pittsburgh Epidemiology of
Diabetes Complications Study III. Arch Intern Med 1990; 150: 1218-1222.
Maser RE, Lenhard JM, DeCherney SG. Cardiovascular Autonomic
Neuropathy: The Clinical Significance of Its Determination. Endocrinologist
; 10: 27-33.
Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between
cardiovascular autonomic neuropathy and mortality in individuals with diabetes:
a meta-analysis. Diabetes Care. 2003 Jun; 26(6):1895-901.
Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation
; 115:387–397.
Tesfaye S, Boulton AJ , Dyck PJ , Freeman R , Horowitz M , Kempler P,et al.
Toronto Diabetic Neuropathy Expert Group.Diabetic neuropathies: Update on
definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes
Care. 2010; 33(10):2285–2293.
Jadzinsky M, Fuente G. Neuropatía diabética, periférica y autonómica.
Diabetes Mellitus. M. Ruiz. 4ta ed. Buenos Aires. Akadia, 2011; p. 595- 612.
Dimitropoulos G, Tahrani AA, Stevens MJ. Cardiac autonomic neuropathy in
patients with diabetes mellitus. World J Diabetes. 2014; 5:17.
The Criteria Committee of the New York Heart Association. Nomenclature and
Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed Little,
Brown & Co; Boston, Mass: 1994. pp. 253–256.
Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al.
Using Standardized Serum Creatinine Values in the Modification of Diet in
Renal Disease Study Equation for Estimating Glomerular Filtration Rate. Ann
Intern Med. ; 145:247–254.
National Kidney Foundation. KDOQI™ Clinical Practice Guidelines and Clinical
Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J
Kidney Dis. 2007; 49 suppl 2:S1-S180.
Voulgari C, Psallas M , Kokkinos A , Argiana V , Katsilambros N , Tentolouris N .
The association between cardiac autonomic neuropathy with metabolic and
other factors in subjects with type 1 and type 2 diabetes.
J Diabetes Complications. 2011 May-Jun; 25(3):159-67.
Dyck PJ, Davies JL, Wilson DM, Service FJ , Melton LJ 3rd, O'Brien PC. Risk
factors for severity of diabetic polyneuropathy: intensive longitudinal
assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes
Care. 1999 Sep; 22(9):1479-86.
Moţăţăianu A, Bălaşa R , Voidăzan S , Bajkó Z . Cardiovascular Autonomic
Neuropathy in Context of Other Complications of Type 2 Diabetes Mellitus.
Biomed Res Int. 2013; 2013:507216.
Vinik AI, Murray GL. Autonomic neuropathy is treatable. US Endocrinol 2008;
:82–84.
Stephenson JM, Kempler P, Perin PC, Fuller JH. Is autonomic neuropathy a
risk factor for severe hypoglycaemia? The EURODIAB IDDM Complications
Study. Diabetologia. 1996 Nov; 39(11):1372-6.
Yun JS, Kim JH, Song KH , Ahn YB , Yoon KH, Yoo KD et al. Cardiovascular
Autonomic Dysfunction Predicts Severe Hypoglycemia in Patients with Type 2
Diabetes: A 10-Year Follow-up Study. Diabetes Care. 2014; 37(1):235-41.
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
The Faculty of Medical Sciences Journal (RFCM) subscribes to the Open Access policy and does not charge authors fees for publishing, nor does it charge readers fees for accessing published articles (APC).
